Victoria M Richon

This inventor holds 28 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Cancer Treatment. Top assignees: Sloan-Kettering Institute for Cancer Research, Epizyme, Inc., Merck Hdac Research, LLC. Active years: 2003-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Victoria M Richon. Retrieved from https://idiyas.com/inventor/victoria-m-richon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 12)

% Patents Active = 50.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 4.4

ph-index = 10

Forward Citations = 327(Granted Patents)

Location History:

New York, NY (US) (2003 - 2008)
Rye, NY (US) (2006 - 2011)
Wellesley, MA (US) (2007 - 2023)

Company Filing History:

12 out of 519

Sloan-Kettering Institute for Cancer Research

Merck Hdac Research, LLC

5. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2023

Loading Chart...

Areas of Expertise:

EZH2 Inhibitors

HDAC Inhibitors

Cancer Treatment

Purine Compounds

Lymphoma

Leukemia

Histone Deacetylase

Polymorphs

Cytodifferentiating Agents

Antibodies

Mesothelioma

Cancer Therapies

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11633420 - Method of treating leukemia (2023-04-25),

2. 10881680 - Method of treating leukemia (2021-01-05),

3. 9949999 - Inhibitors of human EZH2, and methods of use thereof (2018-04-24),

4. 9597348 - Method of treating leukemia (2017-03-21),

5. 9333217 - Inhibitors of human EZH2, and methods of use thereof (2016-05-10),

6. 9096634 - Substituted purine and 7-deazapurine compounds (2015-08-04),

7. 8895245 - Inhibitors of human EZH2 and methods of use thereof (2014-11-25),

8. 8691507 - Inhibitors of human EZH2 and methods of use thereof (2014-04-08),

9. 8580762 - Substituted purine and 7-deazapurine compounds (2013-11-12),

10. 8101663 - Polymorphs of suberoylanilide hydroxamic acid (2012-01-24),

11. 8067472 - Methods of treating Hodgkin's and non-Hodgkin's lymphoma (2011-11-29),

12. 7879865 - Treatment of cancer of the brain using histone deacetylase inhibitors (2011-02-01),

13. 7851509 - Polymorphs of suberoylanilide hydroxamic acid (2010-12-14),

14. 7816499 - Antibodies that selectively bind HDAC9 (2010-10-19),

15. 7799803 - Hydroxamic acid compounds and methods of use thereof (2010-09-21),

Title: Victoria M. Richon: Innovator in Cancer Treatment

Introduction: Victoria M. Richon, based in Wellesley, MA, has made significant contributions to the field of cancer research, amassing an impressive portfolio of 28 patents. Her pioneering work focuses on innovative methods for treating leukemia and other cancer disorders, exemplifying her commitment to advancing medical science.

Latest Patents: Among her latest patents, Victoria Richon has developed a method of treating leukemia that addresses disorders linked to DOT1L-mediated protein methylation. This invention involves the administration of DOT1L inhibitor compounds and pharmaceutical compositions, offering new hope for patients suffering from cancer.

Career Highlights: Throughout her career, Richon has worked with esteemed organizations such as the Sloan Kettering Institute for Cancer Research and Epizyme, Inc. Her efforts in these institutions have contributed significantly to the advancement of oncology and therapeutic methods for treating complex diseases.

Collaborations: Victoria has collaborated with notable professionals in her field, including Thomas Allen Miller and Paul A Marks. These partnerships reflect her commitment to interdisciplinary research and innovation, further enhancing the impact of her work.

Conclusion: Victoria M. Richon’s extensive patent portfolio and collaborative efforts in cancer research highlight her as an influential inventor and innovator. Her dedication to developing new treatment methods continues to shape the future of cancer therapy.

Profile summary based on public USPTO records.